Publications by authors named "Matthew Lindon"

Claim this Profile
S
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.
David J Hirst, Paul Bamborough, Niam Al-Mahdi, Davina C Angell, Heather A Barnett, Matthew J Lindon

J Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.
Philip G Humphreys, Stephen J Atkinson, Paul Bamborough, Rino A Bit, Chun-Wa Chung, Matthew J Lindon

J Med Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'.
David J Hirst, Martin Brandt, Gordon Bruton, Erica Christodoulou, Leanne Cutler, Matthew Lindon

Bioorg Med Chem Lett· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of a Highly Selective and -Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins.
Alex Preston, Stephen Atkinson, Paul Bamborough, Chun-Wa Chung, Peter D Craggs, Matthew Lindon

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
Jonathan T Seal, Stephen J Atkinson, Helen Aylott, Paul Bamborough, Chun-Wa Chung, Matthew Lindon

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Christopher R Wellaway, Paul Bamborough, Sharon G Bernard, Chun-Wa Chung, Peter D Craggs, Matthew J Lindon

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
Michael A Clegg, Paul Bamborough, Chun-Wa Chung, Peter D Craggs, Laurie Gordon, Matthew Lindon

J Med Chem· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Matthew Lindon

Science· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening.
Christopher R Wellaway, Dominique Amans, Paul Bamborough, Heather Barnett, Rino A Bit, Matthew J Lindon

J Med Chem· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Robert P Law, Stephen J Atkinson, Paul Bamborough, Chun-Wa Chung, Emmanuel H Demont, Matthew Lindon

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.
Philip G Humphreys, Paul Bamborough, Chun-Wa Chung, Peter D Craggs, Laurie Gordon, Matthew Lindon

J Med Chem· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells.
Jingjun Li, Jing Ma, Guofeng Meng, Hong Lin, Sharon Wu, Matthew Lindon

Stem Cell Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Peiling Chen, Apirat Chaikuad, Paul Bamborough, Marcus Bantscheff, Chas Bountra, Matthew Lindon

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Natalie H Theodoulou, Paul Bamborough, Andrew J Bannister, Isabelle Becher, Rino A Bit, Matthew Lindon

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.
David F Tough, Huw D Lewis, Inmaculada Rioja, Matthew J Lindon, Rab K Prinjha

Br J Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
Antje Dittmann, Thilo Werner, Chun-Wa Chung, Mikhail M Savitski, Maria Fälth Savitski, Matthew Lindon

ACS Chem Biol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor.
Heng Xu, Haibo Zhang, Linbo Luan, Yan Xu, Chengyong Li, Matthew Lindon

Bioorg Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxazolidinones as novel human CCR8 antagonists.
Jian Jin, Yonghui Wang, Feng Wang, Jeffery K Kerns, Victoria M Vinader, Matthew J Lindon

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.
Stephen J Lewis, Adrian L Smith, Joseph G Neduvelil, Graeme I Stevenson, Matthew J Lindon

Bioorg Med Chem Lett· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis